KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) EBIT Margin (2017 - 2025)

Biomarin Pharmaceutical's EBIT Margin history spans 16 years, with the latest figure at 5.1% for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin fell 2670.0% year-over-year to 5.1%, compared with a TTM value of 12.71% through Dec 2025, down 425.0%, and an annual FY2025 reading of 12.71%, down 425.0% over the prior year.
  • EBIT Margin for Q4 2025 was 5.1% at Biomarin Pharmaceutical, up from 6.02% in the prior quarter.
  • The five-year high for EBIT Margin was 33.55% in Q2 2025, with the low at 14.65% in Q4 2021.
  • Average EBIT Margin over 5 years is 8.08%, with a median of 6.29% recorded in 2023.
  • Year-over-year, EBIT Margin skyrocketed 2128bps in 2022 and then tumbled -2670bps in 2025.
  • Tracing BMRN's EBIT Margin over 5 years: stood at 14.65% in 2021, then surged by 83bps to 2.43% in 2022, then skyrocketed by 273bps to 4.22% in 2023, then soared by 412bps to 21.6% in 2024, then tumbled by -124bps to 5.1% in 2025.
  • Per Business Quant, the three most recent readings for BMRN's EBIT Margin are 5.1% (Q4 2025), 6.02% (Q3 2025), and 33.55% (Q2 2025).